News

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency
Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...
Morningstar2d
Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency | Morningstar
Arcturus has an ongoing global collaboration for innovative mRNA vaccines with CSL Seqirus, and a joint venture in Japan, ARCALIS, focused on the manufacture of mRNA vaccines and therapeutics.
Seeking Alpha5d
ARCT Arcturus Therapeutics Holdings Inc. - Seeking Alpha
A high-level overview of Arcturus Therapeutics Holdings Inc. (ARCT) stock. View (ARCT) real-time stock price, chart, news, analysis, analyst reviews and more.
William Blair Reaffirms Their Buy Rating on VistaGen Therapeutics (VTGN)
Detailed price information for Vistagen Therapeutics Inc (VTGN-Q) from The Globe and Mail including charting and trades.
Urea Cycle Disorders Market to Register Sustainable Growth During the Study Period (2020–2034) | DelveInsight
Urea Cycle Disorders Market to Register Sustainable Growth During the Study Period (2020–2034) | DelveInsight According to DelveInsight’s analysis, the growth of the urea cycle disorders market is ...
Seeking Alpha5d
ARCT Arcturus Therapeutics Holdings Inc. - Seeking Alpha
Get the latest news and real-time alerts from Arcturus Therapeutics Holdings Inc. (ARCT) stock at Seeking Alpha.
Taiwan News2d
mRNA Vaccines and RNAi Therapeutics Market to Surge to US$ 8,210.2 Million by 2030, Registering a CAGR of 31.3% from 2022
The global mRNA vaccines and RNAi therapeutics market size was US$ 707.9 million in 2021. The global mRNA vaccines and RNAi therapeutics market size is estimated to reach US$ 8210.2 million by 2030, ...
pharmaphorum2d
FDA clears first migraine DTx from Click Therapeutics
Click Therapeutics' digital therapeutic (DTx) CT-132 has been approved by the FDA, becoming the first treatment of its type in the US for preventing attacks in people with episodic migraine.